Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 151 matching trials from the live ClinicalTrials.gov search.
Filters: "early Alzheimer" Condition: Mild Cognitive Impairment Clear all
Active, not recruiting Phase 2 Interventional

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

NCT06223360
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Low Dose Benfotiamine, High Dose Benfotiamine, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 89 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 13, 2026, 4:17 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

ScentAware and OCT in MCI vs HC

NCT06377241
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
ScentAware, UPSIT
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 13, 2026, 4:17 PM EDT
Recruiting Not applicable Interventional

Early-Stage Partner in Care Living Alone Plus

NCT06962111
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment (MCI), Alzheimer Disease
Interventions
Psychoeducational skills training intervention
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
60 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 13, 2026, 4:17 PM EDT
Recruiting Phase 2 Interventional

Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial

NCT06601933
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Cognitive Training
Interventions
Cognitive Training
Other
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 89 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
Miami, Florida • New York, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 13, 2026, 4:17 PM EDT
Active, not recruiting Phase 1 Interventional

A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment

NCT05040217
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
AAV2-BDNF Gene Therapy, AAV2-BDNF Gene Therapy
Genetic · Biological
Lead sponsor
Mark Tuszynski
Other
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
La Jolla, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 13, 2026, 4:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

NCT01078636
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
55 Years to 90 Years
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 13, 2026, 4:17 PM EDT
Completed Not applicable Interventional

My Healthy Brain: Preserving and Promoting Brain Health Through Evidence-based Practices

NCT04537728
View directory record Official record
Conditions
Aging, Mild Cognitive Impairment, Dementia, Old Age; Dementia, Cognitive Decline
Interventions
My Healthy Brain Version 2
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 13, 2026, 4:17 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mindfulness for Cognition in Early-stage Alzheimer's Disease

NCT06792877
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, TBI (Traumatic Brain Injury), Aging, Healthy Elderly, Alzheimer&Amp;Amp;#39;s Dementia (AD)
Interventions
Mindfulness Intervention, Waitlist then mindfulness
Behavioral
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
50 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 13, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Results available

Endothelial Facilitation in Alzheimer's Disease

NCT01439555
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Simvastatin, L-Arginine, Tetrahydrobiopterin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
55 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 13, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions

NCT00870974
View directory record Official record
Conditions
Parkinson Disease, Huntington Disease, Autistic Spectrum Disorders, Fragile X Syndrome, Alzheimer Disease, Mild Cognitive Impairment
Interventions
[18F]FPEB
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 13, 2026, 4:17 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Tennessee Alzheimer's Project

NCT05372172
View directory record Official record
Conditions
Aging, Alzheimer Disease, Biomarker, Cognitive Dysfunction, Mild Cognitive Impairment, Dementia, Cognition
Interventions
none, observational study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 13, 2026, 4:17 PM EDT
Not yet recruiting No phase listed Observational

A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease

NCT07864623
View directory record Official record
Conditions
Alzheimers Disease
Interventions
No Intervention
Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
Not listed
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 13, 2026, 4:17 PM EDT
Terminated Phase 2 Interventional Results available

Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease

NCT04795466
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Canakinumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Charlestown, Massachusetts • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 13, 2026, 4:17 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Early-onset Alzheimer's Disease Study Protocol

NCT03507257
View directory record Official record
Conditions
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Flortaucipir, Florbetaben, Fluorodeoxyglucose
Drug
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 64 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
18
States / cities
Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 13, 2026, 4:17 PM EDT
Completed Phase 1Phase 2 Interventional

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

NCT04381468
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Pepinemab, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
San Diego, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 13, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Results available

Effects of Atomoxetine in Mild Cognitive Impairment

NCT01522404
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 13, 2026, 4:17 PM EDT
Recruiting Not applicable Interventional

NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASE

NCT07667478
View directory record Official record
Conditions
Alzheimer s Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Mild Dementia
Interventions
repetitive transcranial magnetic stimulation (rTMS), sham repetitive transcranial magnetic stimulation rTMS
Device · Other
Lead sponsor
Chi-Ying (Roy) Lin
Other
Eligibility
55 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 13, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Treating Hyperexcitability in AD With Levetiracetam

NCT03875638
View directory record Official record
Conditions
Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment
Interventions
Levetiracetam, Placebo oral capsule
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 13, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT01661673
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
EVP-0962, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
45 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 13, 2026, 4:17 PM EDT
Enrolling by invitation No phase listed Observational

Integrating eSAGE With EHR Data Using Machine Learning for the Early Detection and Monitoring of Cognitive Impairment in Individuals

NCT06017505
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Mild Cognitive Impairment, Worried Well
Interventions
electronic self administered gerocognitive examination (eSAGE)
Diagnostic Test
Lead sponsor
Douglas Scharre
Other
Eligibility
50 Years and older
Enrollment
1,486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 13, 2026, 4:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)

NCT01370954
View directory record Official record
Conditions
Early Memory Loss, Mild Cognitive Impairment, Alzheimer's Disease, Vascular Dementia
Interventions
CerefolinNAC®
Other
Lead sponsor
Pamlab, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Oct 13, 2026, 4:17 PM EDT
Terminated Phase 1 Interventional

Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study

NCT03748303
View directory record Official record
Conditions
Alzheimer Dementia
Interventions
Allopregnanolone
Drug
Lead sponsor
University of Arizona
Other
Eligibility
55 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 13, 2026, 4:17 PM EDT
Active, not recruiting No phase listed Observational

A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)

NCT02951598
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Florbetapir F 18 PET Scan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
77
States / cities
Anaheim, California • Imperial, California • Irvine, California + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 13, 2026, 4:17 PM EDT
Active, not recruiting Phase 2 Interventional

Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

NCT04784416
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Active tPBM-2.0, Sham tPBM-2.0, 18F-MK-6240
Device · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years to 85 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 13, 2026, 4:17 PM EDT